Perceptions of risk and therapy among patients with Barrett's esophagus: a patient survey study. Issue 4 (21st September 2017)

• Record Type: Journal Article
• Authors: Stier, M W; Lodhia, N; Jacobs, J; Nozicka, D; Kavitt, R; Siddiqui, U; Waxman, I; Konda, V J
• Is Part Of: Diseases of the esophagus. Volume 31:Issue 4(2018)
• Publication Date: 2017-09-21
• Subjects: Barrett esophagus -- decision making -- endoscopic therapy -- perception -- surveillance; Esophagus -- Diseases -- Periodicals; 616.32
• DOI: 10.1093/dote/dox109
• Languages: English
• ISSNs: 1120-8694

Abstract

SUMMARY: Nondysplastic Barrett's esophagus has a risk of progression to esophageal adenocarcinoma as low as 0.18–0.3% per person per year, and low-grade dysplasia as low as 0.5%. While adherence to guidelines and selection of management options varies, little is known about what modifies patient decision-making. This study aims to evaluate and identify factors that influence patient perceptions of risk and decisions about management. An independently developed and piloted survey was administered to patients at an academic hospital. Risk perception and desire for therapy were assessed using a standard reference gamble paradigm, and responses were stratified based on patient and disease characteristics. Data were analyzed with Student's t and chi-squared tests. A total of 42 of 50 patients with Barrett's esophagus and no prior endoscopic therapy participated (84% response; 76% nondysplastic Barrett's esophagus, 22% low-grade dysplasia, 2% indeterminate for dysplasia; mean age 61 years, 29% female). On average, patients perceived their risk of developing esophageal adenocarcinoma in the next year, 10 years and lifetime as 6, 14, and 19%, respectively. Nearly half viewed their lifetime risk of developing esophageal adenocarcinoma to be the same or higher than diabetes, heart disease, or colon cancer. Although 92% of patients felt surveillance beneficial, only 54% believed endoscopic therapy to be effective in most or all cases. As many as 83% of patients were willing to undergo endoscopic therapy with a hypothetical success rate as low as 70%, and a majority (64%) accepted complication rates up to 30%. Compared to patients with low risk perception of developing esophageal adenocarcinoma, those with high risk perception more often believed their risk for developing esophageal adenocarcinoma was greater than diabetes ( p = 0.04) or colon cancer ( p = 0.002). Those with lifetime low risk perception were less likely to accept modest complication rates (<10%) of therapy ( P < 0.05). Age, gender, degree of dysplasia, lifetime endoscopies and duration of symptoms had no impact on perceived effectiveness of surveillance or therapy, and did not correlate with desire for treatment at varying levels of risk and effectiveness. Patients with Barrett's esophagus overestimate their risk of developing esophageal adenocarcinoma and will accept low success rates and high risk of complications to undergo endoscopic therapy. Baseline risk perception correlates with the desire for endoscopic therapy.